Skip to content
Wall and Schiff – ECMO-assisted CPR episode artwork

Dec 4, 2023 50 min

Wall and Schiff – ECMO-assisted CPR

from Maryland CC Project

Tamar Schiff, MD is an internal medicine trained physician who is completing a postdoctoral fellowship in medical ethics at NYU. In her lecture, she presents key ethical and logistical considerations […]

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Wall and Schiff – ECMO-assisted CPR

0:00 50:18
of matches

Transcript Auto-generated, may contain errors

Thanks everyone for joining us today for Critical Care Grand Rounds. And today I'm really excited about the conversation and the discussion and the lecture for today. So today we're joined by Dr. Tamar Schiff and Dr. Stephen Wall. They're from NYU. And if you haven't read it, I posted in the chat a link to the paper that sort of got me interested in their work. So this paper was published in Critical Care pretty recently and is talking about ECMO and integration with organ preservation in the U.S. and kind of some of the ethical and logistical implications that go into this. And super happy to have here some discussion about some of the ethical implications, but also the logistical and practical implications. And so thank you to Dr. Schiff and Dr. Wall for joining us today.

of share this idea and this concept with us and for allowing us to have this discussion with you. So thank you both for being here. Thank you again for the invitation. I think we're both very excited to be here, both to share our work and then to have hopefully a nice discussion at the end. So as mentioned, I'm Tamarsha. I'm trained as an internal medicine physician, but I'm doing a research postdoc in medical ethics. And most of my work is in transplant ethics. And then you'll hear from Dr. Steve Wall, who's a tenured associate professor in emergency medicine, population health, and who serves as my mentor in a lot of the work in this domain. So these are just very briefly our disclosures. I'll let everyone take those in. And then the objectives we shared ahead of today's talk.

I just do want to signpost so people know where we're going to go in the next 45 to 50 minutes. I'll just very briefly touch on the purpose and data behind the use of ECMO-resuscitation or ECMO-assisted CPR, ECPR, and then using the same circuit in a modified way for organ preservation ahead of recovery for transplantation. So that's termed normothermic regional perfusion, NRP. I'll then review the reports of the combined ECPR and NRP programs in countries outside the U.S. and really spend most of the time thinking about the ethical and logistical considerations and implementing those type programs here in our...

interesting and fractured healthcare system. And then I'll really end on just trying to emphasize what we think is the most important thing, which is a focus on proactive ethics in planning and designing these types of programs. And I'll kick it over to Steve to underscore the importance of proactive ethics as he reviews lessons from his very hands-on experience in implementing a kidney UDCD program here in New York. Okay. So again, this part, I really will try to be brief, more than happy to talk about it more in the discussion, just so that we get to the meat of this, which will hopefully be the ethics and the other considerations. So very briefly, ECMO, as you mentioned, I'm sure you guys have a pretty active program in this, can be used for...

CPR. Most commonly, this is people who have failed conventional CPR and started termed refractory and then go on to be cannulated with ECMO used for further resuscitation purposes. The data on this is promising, but most of the published reports are single-centered and observational, and there's pretty varying and inconsistent eligibility criteria across these studies, so it's hard to generalize. But it does seem that very specific patient selection, rapid initiation of... ECMO for resuscitation and then regionalization of programs where there's very tight coordination between EMS services and hospitals to which patients are going to be taken. These are the important factors in making eCPR more effective for resuscitating individuals. That's weighed against the, of course, many potential complications, including bleeding, hemolysis, thrombosis, a host of other complications. And so I raise that very superficially here just to say that for all its promise, we do need to consider if some people would have done just as well with standard CPR and may actually suffer more complications from ECMO being employed. And that's going to be.

kind of a continuous theme when I get to the ethical considerations of these combined programs. So in the same vein, the same circuit, again, can be used not for resuscitation, but after death, simply to preserve organ viability ahead of organ recovery for transplantation purposes. And this, again, is termed normothermic regional perfusion. This little schematic is just showing that, again, it is using a modified version of the same ethmo circuit, but if you are just trying to recover abdominal organs, you would occlude any blood flow above the level of the diaphragm. And if you want to include thoracic organs, then occlude at the level of the carotid. So again, in this scenario, the...

purpose of ECMO is not resuscitation. It is simply to perfuse organs after death to increase their viability upon transplantation. So here I just want to touch on kind of the alphabet soup that you can't avoid when you get into this. So I'll start with, because the focus of this is really going to be integrating the prospects of organ donation, it's really important to keep in mind that there's this consensus tenet of the dead donor rule, which is that an individual cannot be made dead for the purposes of recovering their organs. So death has to be declared before any life-sustaining organs are removed. And then again, just touching on all the acronyms. So we know that most organs that we recover currently are after an individual is declared dead by neurological criteria. So that's either.

uh donation after neurological death or brain death dnd dvd and then uh what we're hoping to explore is the potential of the increased donor pool after circulatory respiratory uh criteria of death so dcd and that can either happen in happen in an uncontrolled setting which someone has uh a unexpected cardiac arrest or in a controlled setting which like sustaining treatment is withdrawn again in a very controlled environment and then uh death is declared by circulatory criteria and the person goes on to donate their organs uh there are these accepted uh master classifications of these different categories. So again, first and second being uncontrolled if someone is either found dead or witnessed cardiac arrest. In both cases, these are sudden and unexpected events. And category three being a controlled environment in which life-sustained treatment is withdrawn. And then four, which I think we talk about because it happens less frequently, is if someone does have a cardiac arrest after neurological determination of death.

We'll focus on that one the least. This is really just to drive home the point. So again, I'm using NRP for donation after circulatory respiratory criteria of death. So in a very broad strokes, if someone undergoes, if someone suffers cardiac arrest, undergoes CPR, moves on to eCPR, so they're already cannulated and hooked up to the ECMO. In these scenarios, then, if there is not, and they don't meet criteria for death by neurological criteria, but there is not an anticipation that they will recover to the point of meaningful neurological activity. And there is the...

decision to withdraw life support for the purposes of organ donation. In this scenario, again, the ECMO is, I'm going to use inexacting terms here, but turned off. The person is declared dead by cardiac criteria after a hands-off period in which we make sure there's no autoresuscitation of the heart. And then after occlusion of blood flow, either at the level, again, of the diaphragm or the carotids, the circuit is turned back on. But now it's not for resuscitation purposes. It's simply to perfuse the organs that we're trying to recover. So that's controlled DCD. And then in uncontrolled DCD, again, this is someone who's either witnessed cardiac arrest or found dead. So they either have or have not undergone CPR.

But in this scenario, they're really cannulated simply for the purpose of NRP. They've never had a trial of eCPR, and they go on to donate through the UDCT pathway. So I want to now review the reports that have been published of combined eCPR, UDCD using NRP protocols. And the real undergirding rationale of all of these is that we know that using ECMO for CPR does offer select patients a better chance of resuscitation with good neurological criteria. Again, we still have a ways to go in determining which patients those would be. And we also know that organs recovered after the use of NRP do show very promising results in terms of there being more viable and in turn having better outcomes for the transplant recipient.

taking these two prospects together, the idea is that combining these programs really allows for us to maximize lives saved. So the first study was in Porto, Portugal. This was a prospective observational study of in and out of hospital cardiac arrest in about a year and a half long period. This is their protocol. I'll just review it very briefly. So after someone is refractory to standard cardiac, to standard CPR, excuse me, they're considered for eCPR based on clinical criteria. If they meet these criteria, then they go on to receive CPR. This again is a very, this is their...

EMS and hospital system allow regionalization and very close coordination that allows quick transport to hospitals. If they don't meet ECPR criteria, then they are considered for UDCD. And if they go on to that pathway, then NRP is employed. So in this study, you can see what they found is that of the individuals who received ECPR. 15 obtained ROS, eight of those were weaned from ECMO, and six were then discharged with good neurological criteria. Of those who were not able to be weaned from ECMO, one was declared dead by neurological criteria, and two kidneys were recovered and transplanted. But then in the UGCT arm, 33 of the 40 individuals were successfully cannulated for NRP, and among those, they recovered one liver and 62 kidneys, 44 of which were successfully transplanted. So you can see a very increased donor pool from incorporating these two protocols.

A second study that was reported was in Florence, again, a prospective observational study. This one was just out of hospital cardiac arrest, again, for about a year and a half study period. So they reported that of their 134 eligible patients, eligible by being under 65, of those that... obtained ROSC by standard CPR. 15 of those died and seven became donors after death by neurological criteria. Of the 86 that did not achieve ROSC, 26 underwent eCPR and eight of those went on to be donors. And then 25 went on to be UDCD donors without undergoing eCPR. So their impressive conclusions here were that of the whole study population, there were 40 donors, 25 of which, so the majority came from the UDCD pathway. So again, incorporating these two protocols allows for a really impressive broadening of the donor pool.

And this will be the final study I review. So this one was in Lisbon and actually presented kind of a expansion of the Porto original study. This one was retrospective with data for a two-year study period. Similarly, again, these were among patients admitted to their ICU. They were either considered for ECPR and if not then considered for DCD donation.

So among the people who received eCPR, five of them died. One was discharged with good neurological criteria. And then among the UDCD patients, I'll mention here, they call it donors refused, but this isn't, I believe only one was the family's refusal. The rest were refused to be accepted as donors due to clinical criteria, but 13 went on to be effective donors. So they transplanted 26 kidneys. And the important part here is that that really represents about a 20% increase in the kidney transplant activity at their center during the study period. So a great expansion of their ability to recover and transplant kidneys by employing UDCD.

I hope I haven't saturated anyone yet. This is now going to get into the meetup hour paper where we were really looking at. considering implementing such a program here in the U.S., being very mindful of the differences between the U.S. healthcare systems and the countries that are represented in these other studies, Portugal and Italy. This is our kind of cutely termed concept map. We've shown this to a few when we describe this as a simplified version. They kind of laugh in our face because this is hardly simplified, but it is from the true protocol. So I'll just walk through this very briefly. So again, the protocol that we're looking at is one in which someone suffers cardiac arrest if this is termination or resuscitation. If they go on to receive eCPR, obviously they can always re-arrest once they get to the point of achieving ROSC.

they can go on to standard post-arrest care. If they do not achieve ROSC, they're considered for eCPR, which of course can be declined due to clinical criteria. If not, though, they go on to receive eCPR from which they can, again, recover, be weaned from ECMO, and go on to post-arrest care. They can go on to be transitioned to destination therapy, like an LVAD or a heart transplant. They can go on to be declared dead by neurological criteria while on ECMO.

Or there will be those who do not meet criteria for neurological death, but are not able to be weaned from ECMO. And those will either be those with very poor neurological function, in which sometimes the family or per the person's wishes may go on to have life support withdrawn and go on to be controlled DCD donors. Or, and I will put a pin in this one a little bit and get back to it in a couple of minutes, there are the very rare cases of individuals who are successfully resuscitated with the use of ECMO, do have good neurological functions, presumably could be capacitated and participating in their own care decisions, but are unable to be weaned from ECMO and are not. eligible for a different destination therapy so they're really um on this what has been termed in literature bridge to nowhere and i'll get back to that in a second the second arm and these final bubbles just represent the kind of the destinations in terms of donation decisions This lower arm is for individuals who do not end up receiving eCPR and are considered for cannulation for the use of ECMO for regional perfusion to become UDCD donors. And they can, of course, go on not to donate or to proceed with the UDCD pathway. So that is the very pared down protocol that we're looking at. And the real thrust of our project that was published in this paper was looking at the important ethical considerations that rise at kind of central nodes, these color coded ones along the way.

And I'll get back to this concept in a second. But we really the real impetus was that you need to sort out the ethical and then, of course, logistical, legal, et cetera, considerations before implementation of protocol, because sorting these out and doing this equitably and ethically is just as important as sorting out the clinical criteria that are important. So with that in mind, I'm just going to quickly walk through the what we thought were the most key ethical, ethical, legal considerations at each one of these kind of central points along the protocol. The first is when considering the initiation of ECPR. Because our healthcare system functions so disparately in different geographies, there is obviously a different resource availability depending on institutions. Thinking about widely disseminating eCPR programs here in our country really requires consideration of how to best ensure equitable access to this technology. A second consideration is that as this becomes a more prevalent practice, the public will similarly need to be educated about this being a consideration in end-of-life decisions. And so when normally we think about having a code status decision, it is around conventional CPR.

the considerations that ECPR brings along, including, again, the complications that can potentially result from ECMO, et cetera, will be ones that need to be included in a standard code status discussion. The next place we looked, again, is this consideration of what can happen once a patient has undergone ECMO for resuscitation purposes. The first is that there are, again, there's not necessarily uniform practice or consensus guidelines around which point, based on a patient's clinical outcome after ECMO, we can consider withdrawing ECMO if it's... Again, this isn't an exact term. We obviously are trying to get away from the use of the word futile, but if it's deemed futile or medically inappropriate, at what point or with what criteria can you consider withdrawing it? Again, there is just more research and public discussion to be done around the risk of complications of ECMO. And then finally, this very emotionally and ethically fraught scenario that I mentioned at the Bridge to Nowhere and the clinical teams, but also individuals and their family members having to consider this a possible outcome in making the decision of whether to initiate ECMO or not.

Here, once we consider controlled donation after cardiac death, I'll first talk about the second bullet point. We again don't have strict consensus guidelines around how long we wait for autoresuscitation. So again, in these scenarios, the individual is on ECMO, but the decision has been made to withdraw life-sustaining treatment for the purposes of organ donation. So the ECMO is turned off. They are then declared dead after this period for which we monitor for autoresuscitation, which is termed the hands-off period.

But there have been reports of protocols using anywhere from two to 20 minutes for this hands-off period. The majority use a five-minute window, but there are, again, no consensus guidelines on this. And the second and I think much bigger ethical issue relevant to CDCD is this concept of permanence or irreversibility in declaration of death. So I'll just spend a couple of minutes on that quickly. So this is the language from the Uniform Determination of Death Act. And this is model legal language that's written by the Uniform Law Commission. And in turn, every state has... That's a little premature, sorry. Every state has...

enacted a state-specific Determination of Death Act, but they're all based on this language and are pretty uniform across states. So the uniform determination of death defines an individual to be dead once that individual has sustained either an irreversible cessation of their circulatory respiratory function or irreversible cessation of all functions of the brain. And then, of course, in either of these scenarios, that determination of death has to be done in accordance with acceptable medical standards. So where this gets tricky is that this is going to get a little semantic, but these are the way these two terms, irreversibility and permanence, are used pretty consistently in literature. So irreversible means cannot be reversed.

regardless of what intervention is employed. So the irreversible cessation of either circulatory and respiratory functions or of the entire brain, no matter what intervention we apply, will not be able to be reversed. It's irreversible. permanence is used to mean will not be reversed. So this person has been declared dead. In theory, we could try certain resuscitation interventions, but the decision has been made not to try those. Again, usually, not usually, always in accordance with the wishes of the individual or their surrogate decision maker. And so they will never return these functions, whether they're circulatory, respiratory, or the brain functions will not return. It's not because they're strictly irreversible, but it's because we will not try to reverse them. And the very clear example of this that I think is common and we all feel rather comfortable with is a patient who has elected to be DNR and suffers cardiac arrest.

In theory, that cardiac arrest is reversible if we were to try to resuscitate them, but they are permanently dead because in accordance with their wishes, we are not going to try to resuscitate them. So what happens in practice, and again, this is pretty accepted now, is that even though the language reads irreversible, we treat it as permanence rather than irreversibility. A second layer to this is that there's a lot of controversy in the use of NRP after the determination of death, and that some people feel that if someone is declared dead by circulatory respiratory criteria, and then you restart their circulation, you're undermining that initial declaration of death. However, there is a host of people, but here I'm quoting a scholar Burnett about basically unifying the two determinations of death.

So the real thesis here is that the whole point of circulatory death is that it leads to eventual neurologic death. And the neurologic death is really the important part here. That is when the individual ceases to exist as an individual. And so if we declare someone dead by circulatory criteria and then allow the neurological criteria to complete its course by never allowing the brain to be reperfused, we are not undermining the declaration of death even if we restart circulation in the rest of the body. Because the real point here is that neurological death is the end result. And that will complete because, again, we're either including at the level of carotids or at the level of the diaphragm, even though we are restarting circulation.

not for the purposes of resuscitation, but just for the purposes of perfusing specific organs without undermining the declaration of death of the organism as a whole. Okay, so again, this is just to show that for the people who are critics of using NRP, especially for recovery of thoracic organs of the heart, especially, they, again, argue that it undermines the declaration of death by circulatory criteria. And so that camp is really proponents of these alternatives. So you can either, instead of doing in situ NRP to reperfuse the organs, you could do super rapid recovery of the heart, in which case usually the donor and the intended recipients are co-located, or there's a rapid recovery and cold transport of the heart.

The limitations of super rapid recovery is that you can't do any functional assessment of the organ in situ before preparing it for the recipient. There is an increased warm ischemic time that comes with using this protocol, and the urgency of having to get the organ out of the body and into the recipient really does lead to semi-atrogenic complications. The other alternative is rapid recovery and ex-situ, this picture down here, an ex-situ machine perfusion. a little um reductive you know in in situ nrp we can say that we are ligating the vessels or occluding blood flow and then restarting perfusion of the heart in the body while as in ex situ we're doing all the same things we're occluding the vessels or severing the vessels but we are restarting perfusion of the heart outside of the body and you know of course there are people who think that whether it's inside or outside the body makes a big difference ethically um but again with ex situ um compared to super rapid recovery and again in similar to nrp you do decrease ischemic time But you don't get as much of a functional assessment in the body as you could with NRP. And it is extremely expensive. I've seen quotes of about 40,000 per heart to use exotuberfusion. So NRP, again, in addition to, you know, in our view, being ethically defensible, it does reduce the time constraints for organ assessment and recovery. And so reduces those iatrogenic complications and allows for this real functional assessment of the organ before it's given to the recipient. And then in turn, again, compared to super rapid recovery, it does reduce injury due to warm ischemic time.

So now I'm getting back for our very final box here. This is the home stretch. So just the ethical considerations in this bottom arm in which someone has not undergone eCPR, but is instead cannulated for the purposes of NRP. Here, really, it is important to think about the differences in our system compared to those countries, Portugal and Italy, in which these combined programs have been. reported because we do not have or rather i'll say we have an opt-in organ donation system and so someone really has to give their permission as opposed to for example in portugal where they have an opt-out so the baseline assumption is someone will be an organ donor unless they have registered or the family has indicated otherwise so in our country there is that um kind of stop measure of wondering whether it's okay to cannulate someone if we don't know whether they're an organ donor and the assumption is that they're not because we have an opt-in system so this really raises the um question of whether it would be okay to cannulate someone for the purposes of um preserving their organs until we determine whether their decision is to become an organ donor or not. This also raises questions of whether the average person who is authorizing organ donation at the DMV or through a state registry, are they considering the option that their body may be intervened on in this way after death be cannulated? It's rather invasive, and would they still be comfortable being an organ donor? And finally, because of these equity issues, do we feel comfortable that a program that does not have eCPR capabilities would then use ECMO purely for organ?

preservation purposes. And again, with the historical distress of certain communities of the medical system, could that have ripple effects in terms of people feeling that this is a further abuse? So with all these questions in mind, I will very briefly review our recommendations. And again, our biggest push here is for employing proactive ethics, trying as best we can to address these considerations before implementing a protocol. Obviously, implementation will raise things that weren't considered ahead of time. But the point being that we never want to be in a position in as much as we can control to play catch up, to consider the ethics once they've had negative impacts and possibly undermine this whole venture. So first, for this question of equitable access, we...

think that it's really imperative that there be national centralized and iteratively analyzed data of eCPR and NRP. And essentially, this would mean that any program that has eCPR and NRP capabilities would... report their data to a centralized database. And the idea here is that then we could iteratively analyze that data to come up with consensus guidelines that are data and evidence-driven around things like consensus on how to decide when to withdraw, on how long we should wait before we feel comfortable that auto resuscitation will not occur. The second proposal is that NRP really should only be occurring at programs that do have ECPR capabilities. This is both for the optics, again, so that communities don't feel that their bodies are being, or that there's some...

priority being given to obtaining their organs rather than resuscitating them. But also because of resource utilization, it is more ethically permissible to say that we should really only be using, that the use of ECMO should always be first and foremost for life-saving purposes. And when that's not possible, then we can use it for organ preservation. That being said, in programs that are capable of doing both, it's not necessary for an individual to undergo eCPR in order to then be considered for NRP. If they don't meet the clinical criteria for eCPR, then we don't need to go through that pathway just to eventually say that They were cannulated for the purpose of resuscitation and now it's being used for organ preservation if we don't think that using ECMO for CPR would have ever benefited that individual.

Here, as I went through the kind of rigmarole around permanence and reversibility, when the language around the definition of death was being drafted, I think the considerations of ECMO were not really at the forefront or even considered at all. So the legal definition of death really does need reexamination around this topic. And then these are just kind of overarching takeaways that for all of these considerations, and usually for any kind of proactive ethical thrust ahead of implementing some novel protocol, there really is an imperative for maximal transparency at every point. So we know that often in emergency situations, individuals or the family members can be updated, but anytime that is... possible. There should be just maximal transparency between the clinical team and the family of an individual. It should be a process of authorization rather than a one-time conversation and also maximal transparency in terms of individual institutions protocols being freely discussed whether available to the public. And that leads to part two of this, which is that it's really important ahead of implementing these types of protocols to have broad public engagement about every step and every consideration along the way to consider perspectives of stakeholders that maybe those coming up with these protocols or thinking about the implementation strategies have not considered.

And with that, I'll pass it over to Steve. So in the final 10 to 15 minutes, I'm going to do a whirlwind tour. You know, basically all that was in the abstract, but we really have practical experience. And the reason why I reached out to people like Tamar with her expertise in bioethics is that we were being reactive. And I'll give you some examples as we go along. I don't have any personal funding from any private sources. Some of our colleagues do have some funding from Unite Therapeutics, just to put that out there for some grant. And also we have some NIH funding that went into some of these projects I'm talking about.

So I don't know if anyone had a good chance or is a fan of the TED Talks, but back in the day, Tim Harford gave a really great talk on how is it that we solve complex problems? It's really through trial and error and evolution of that. And unfortunately, our research infrastructure is not really geared toward that, but that's what you have to do to get these projects done. So this was the simplified protocol, which we got chuckles from our viewers. I do want to point out one thing just to clarify from before. There actually are three ways to consider.

organ donation after control, donation after cardiac death, or circulatory death, for that matter. In this country, the proper preferred method is just rapid recovery after turning off, but then you can also use external preservation and also re-turning on the NRP circuit. But you see this is a very complicated protocol, even in simplified form. Well, this is the actual protocol. You know, so how the heck do you get your wrap around that? And just one quick thing. I mean, you know, does a body do an echo in the street or did you bring it to the facility? Do you have a regionalized program? I mean, it really gets to be a mess, right? So how do you wrap your hand around it? So what we do is we use two theories. One is called a steep scale process for social change.

And this has been particularly successful in developing countries and also in Appalachia, where they were trying to just reform different things. Like for instance, in Appalachia, a lot of people have dental, severe dental problems because of Mountain Dew. And what they do is they work with communities to try to teach them about better oral hygiene and maybe not having so many sugary beverages. And it worked out quite well. But the reason is, it wasn't just some people telling you don't drink these beverages. It's offer alternatives, work with community, maybe in schools, get it out of the schools or wherever it might be.

The other one is what's called participatory action research, which is very counter to what traditional NIH grants and most grant funders understand. If you put a grant in purely on this, it probably gets shot down. So the question is, how do you use these philosophies, but still have some rigor to it? And essentially what it is, first you define the need. And part of that need, I would say, is proactive ethics. So then you design your program, and then you implement it and evaluate it. And then from those lessons that you learned,

fix it and keep going until you get it right. I mean, this is what businesses do, in fact, why some bookstores survive and others convert to web-based content because people aren't reading books anymore. I mean, this is how society tends to evolve. So I'm going to talk about two proposals about the kidney UDC programs, UDC programs in the United States. One was funded by New York City Health and Hospitals, where I'm at. I have a dual appointment. One at Bellevue Hospital, which is an H&H facility, and the other is New York University School of Medicine. The other one was at Pitt.

So you can see, this is my old boss, Louis Goldfrank. You can see Mayor Bloomberg at the time. I was a kid around. I'm a methodologist. I'm in the background, you know, getting away. But we basically, after engaging all these communities, we implemented a program. And when we had all these, we had town hall meetings, we had focus groups. And these were pretty much the constructs that came up. That's on the left. And on the right are the themes, okay? So there were like clinical, ethical, legal, logistical, and public concerns. And I won't go through them all, but you can see, well, so the public wanted trust. And how would you do that? Separate the teams. Make sure that whoever took care of the patient is not doing preservation.

You know, there's legal issues. You know, and I'll go through a little bit more when I show you the example of the protocol. But the idea is that this is what we had come up with through a lot of discussions with people at the top and at the bottom, so to speak. You know, you want to have some grassroots feeling and actual realization that they contributed to the protocol. All right. So this is what we had to come up with first was, well, okay, we've got, we were going to do some after death. This is the only field, by the way. Okay. Someone died in their home and met QR criteria.

they might be an organ donor if they met certain clinical criteria, whether it's their age or whatnot. The proposal at the time was to say, okay, let's re-hook them up on a Lucas device, re-hook them on the ventilator, bring them to the hospital, put them on NRP, and then go on to organ donation. We were only allowed to consider people who were already pre-registered for organ donation in New York. So that was the whole philosophy at the time for our protocol. Now, I'm bringing this slide up for a good point. What happened was, my friend Brad, he was actually a classmate of mine. He's one of the medical directors of FIDM EMS, a smart department of the city of New York.

You went to an EMS conference and decided, you know, hey, let me just show this idea and get some feedback from our EMS community, right? Well, there was a reporter from USA Today there who completely misunderstood what we're doing, thought we were going to start all these techniques without permission or consent. And actually, at the time, the National Academy of Medicine thought, well, maybe we can start some preservation without prior authorization. But we were just talking to communities. At the time, in fact, we already knew that they wouldn't go with it, so we were going to drop that idea. But yet, this reporter assumed that that's what we were going to do.

And we were called a meat wagon. You know, that was my favorite. Apparently some people, it was old sounding live sketch apparently about meat wagons or something. I don't know. So at any rate, this is what happens when we don't do things for actively, correctly. We came up with a protocol. Essentially there was a lot of stuff that we couldn't control. Like for instance, we couldn't accept anybody who was not an organ donor. Why? Well, according to your public health law, EMS or anybody can only enter an apartment that's going to save their life. If they're dead, then it's the coroner.

So they said, okay, well, you can go in and check to see if they are registered. And if they are, you can consider them. And if not, you can't. But only 18% of people were registered for organization at the time in New York. Just to give you what, that was one of the deal breakers for us. So we actually were active for six months. We should have been active for longer, but we had to pay for detectives to be on the scene. And that really cost us a lot of money to make sure there's nothing untoward for the crime standards. But what we did find out is that...

there actually were a couple of cases that we could have considered. Those are in yellow. It's just that they weren't registered. And then we had another case of a young person who died, not even on this list, you know, seizure in a bathtub, not for lungs, but could have been eligible for kidneys. But because he was so young, they didn't bring him to us. They went to another hospital thinking that they'd resuscitate the guy, you know, but it didn't happen. So when we get all our end of shift notes, everyone really was okay with what we were doing. We also interviewed people after the fact, just to double check. You can see here, this shows like, even though we only had nine approaches.

Only nine on nine, there was nothing that was unethical, nothing that where people were so offended that we shouldn't have been bothering and trying this program. And that was vetted by an ethics committee looking at all of our notes. This is just an example. So once we reached, this was from one of the, it was a note of a participant who was approached, a family member. Once we reached the fifth floor and I could hear a female crying and I thought to myself, this might turn ugly due to the potential state of mind of a loved one. To my surprise, a lady who saw me and she said, oh my God, they're here for her organs, but it's okay, I understand. I mean, this just shows you that people are okay with it as long as you work with them. Pittsburgh had a different problem. They were in hospital. It didn't work because,

they were going to use NRP, but they had to do a neuro check and they didn't want to do neuro checks on dead bodies. We were willing to do it. Okay. But because the whole permanence reversibility logic came to fruition around the same time that we did our work, they tried to use cold perfusion and it didn't work out for them. So one of the things I would suggest is that you think about understanding current events. So right now, for instance, in New York, they're about to start a regionalized ECMO program.

And it's going to be pilot tested in Manhattan. The criteria on the right, I want to highlight something. Most eCPR programs require a bystander CPR. Well, Sydney understands that hardly anyone in New York gets bystander CPR. And in fact, it's regressive because...

In communities that are most vulnerable, their rates are even lower than the general population or white communities for that matter. So in essence, you really should be expanding the criteria. But when you expand criteria, you'll have less percentage of cases going to survive a good neurological outcome. Hence, we probably have some more organ donation opportunities. So this is a good time to kind of consider what's going on in New York and why I enlisted Tamar and others to kind of think through it. You know, and if we relax the criteria more, so long as we're not hurting patients, and that's a big thing Tamar will say, maybe it's okay, but we want to make sure that we're not...

causing undue problems by giving people ECMO when they wouldn't have a good chance of survival. That's also an ethical, right? So again, then there's also this, I was a member of this NHLBI workshop where we looked at xenotransplantation and DCD. And it is a hot topic. There's still a lot of controversy. I call it a fundamentalist point of view where any reinstitution of circulation after death could be construed as violating the dead donor rule. And even some of our colleagues suggest that the physicians could be subject to criminal charges.

all the way to the other spectrum, which is to say, well, maybe we should allow work in a nation to occur before death. I mean, that's rather true, right? Again, we have to follow the laws of law states. There are different interpretations of laws, but we have to understand there's a climate going on here. And if I started a program right now and I didn't reach out to communities, and then some people read this literature that suggests that the doctors doing this should be arrested, well, you can only imagine what that would happen with communities, right? So you have to really work with them and hopefully this might get resolved. Alternatively, which is what we're doing with a lung program now, I went to a lung program that's funded by NHLBI, excuse me,

because we don't need NRP. Okay, well, so knowing that hopefully this can get resolved. But all it is to say is that if you are going to start a program, understand that you want to make sure that your ducks are in a row, people understand these issues. You don't hide them. You bring it out in the forefront and see if they're comfortable with it. Maybe New York is okay with it, but Utah's not. I'm not sure. Utah might be more in favor than New York might not. But the point is that if you don't engage the public first, you can get yourself into trouble. This is an example, actually hypothetical.

of maybe the communities that you'd want to reach out to for this particular program. Again, it's not comprehensive, but you want to do enough. And if you can't go out and meet people on the street, at least have good representatives of those people on the street. We typically will engage with religious leaders because with organ donation, religions tend to have strong opinions about that. But then we'll also reach out to community health workers who represent these communities. That's one way we dealt with it.

but also reach out to the clinicians because these bodies are going to be going to an OR in your hospital. And I'll tell you, like in our hospitals, some of those are the most folk that are mistrusting of organ donation because of bad experiences. So this is what you really want to do. Engage these people. And then also you want to engage the leaders in addition to the people who are doing, you know, in the pits, doing their jobs, because you don't want it to be topped out and forced. And also people should be able to opt out if they have their own reservations about certain things. That's fair too.

This is also to say that if I'm going to do an evaluation, don't just focus on the clinical, okay? So the bioethics, here we have like a, what's called a, I guess I would call this a construct map with themes below. So constructs are acceptance of death declaration, autonomy, and trust, which are some of the tenets of bioethics, not all of them. But you can look here, and these were the things that Tamar mapped out. And there's overlap, but the point is, if I can get at these issues, talking with people while a program is in development and being implemented, I can do case notes, or I can also interview people qualitatively or do focus groups, however it's going to be. But get that information in addition to whether or not the organ works or doesn't work.

On the other side of this is a implementation framework, which is to say you also want to find out the processes. Is it too complicated? You know, is this really impacting other patient care services? Because that's also very important. But we tend to focus more so on the clinical aspects of this. And that's wrong. And this is just to hand me at home, right? So this is a grant that was awarded right now for our lung preservation program. And what did we do? Well, okay, this is what Tamara's talking about. Preemptively, proactively is what I was looking for. Meet with these stakeholders and keep going until you're comfortable and you've got consensus.

Get into it. Start looking at the screening process. Make sure that that's being evaluated and rigor. Look at the safety outcomes. This is primary graft disease for 72 hours, and you'll get survival. But also look at the ethical acceptability. In real time, then also you can go ahead and interview people who've been approached for these organ donations and see how they respond. And this is what's ongoing right now. We're in the planning phase. We're about to roll this out in July.

So, and then this is a table that just says, hey, you know, there's some ethical outcomes that we can look at, right? So what do we look at? Acceptability, what does that mean? Acceptability, you know, I mean, we're using what's called a, like a collaborative decision-making approach or, you know, some kind of deliberation. So people are in the room, shared by a bioethics specialist, and you have other people who at least have knowledge about the clinical processes with an eye towards bioethics, and they can just say, okay, is this reasonable or not? Okay, also have an independent data and safety monitoring community, look at these things for the same. And then also look at the authorization rates, look at, you know, how did people impact it after that?

And these are some things that you can look at. Data can come from anywhere. I'm having a meeting right now. You guys are going to question me about this. Hopefully there's enough time for questions. I'll end in a minute. But I'll take notes. And then that actually gets transferred into my next protocol. But the point is, if you don't take notes and you don't organize them into what's called an action research matrix, there's no rigor to it. So what I can do is I can have summaries here and encode this like a qualitative person would do. And then now I've got proof that, hey, we really did reach out to everybody. And if someone else says, I don't believe you, you can go through this chart.

Okay. And this is just another way of justifying. No, are you going to get it right 100%? Absolutely not. I mean, look at this. Okay. So I'm in a meeting with faith leaders, right? I know it's a little blurry, but you can see this is a simulation dummy, right? So I showed this to them and all of a sudden they were panicked. Like they were just appalled. So that tells you how good simulation dummies are, right? Because it really does simulate what's happening. So what did we do? For the next meeting, we made a cartoon. Okay. And this is much easier to look at. And so now they're understanding the concept without getting scared.

And then this is one more thing just to hammer on the point of why proactive methods are necessary. So we have an NRP ongoing at NYU right now. Vanderbilt's doing it at all these other places. So yeah, we got this great article that came out. And then next thing you know, I got Alex Glazer and Capron saying that all those doctors that are part of the program should be put in jail. I mean, is that really what you want? No. I mean, this is not how we should be doing this, right? We've got to resolve this work beforehand and show that the community was really on board, in which case the community members can write a response to Alex and we don't have to.

This goes to show you how much work is involved. Tamar is in this one little area here, which is being done, but we have lung uncontrolled going on. We had a kidney program in effect, and now I'm actually advising on other projects like Xeno, which I never thought I would as an ER doctor, but that's how life takes you in the research world. With that, I'll stop, and we really would love to have any questions.

Beyond Hope Project with Jason Tharp Beyond Hope Project Welcome to 'Beyond Hope Project,' a beacon of inspiration in the podcast world. Join Jason Tharp as we embark on a transformative journey, exploring stories that awaken the will to start anew and find the strength to rise from setbacks. 'Beyond Hope Project' is about lighting the way to your starting line, not dictating your path. We delve into narratives that foster optimism and belief in a future where dreams become achievements. Each episode is a tapestry of positivity, enthusiasm, and comforting support, resonating with the essence of hope. This podcast goes beyond storytelling; it's a movement of positive change rooted in authenticity and transparency. We provide real tools for real journeys, infusing more hope and joy into the world. 'Beyond Hope Project' stands as a testament to the transformative power of hope and the limitless potential of the human spirit. Join us in transcending boundaries and breaking barriers. Here, we prove dai Veteran Chat Project Kyle Turner Our goal is to reach as many Veterans as we can. We noticed a lot of the podcast personalities tend to be unrelatable to the every day joe. Not taking anything away from anyone just hoping to give more people a place to feel connected to something. KZ and Kyle are Army vets who deployed together for OIF 07-09 and OND. Now close to 15 years later we are finding a way to open up about our issues, and find a way to build a community. Paramedic Philanthropy Project Melissa Ade Podcast by Melissa Ade Bigfoot Information Project Podcast Bigfoot Information Project Occasional conversations with leading researchers and investigators regarding the animal commonly referred to as bigfoot.

Frequently asked questions

How long is this episode of Maryland CC Project?

This episode is 50 minutes long.

When was this Maryland CC Project episode published?

This episode was published on December 4, 2023.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Maryland CC Project episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.